Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Female breast cancer risk in Bryansk Oblast, Russia, following prolonged low dose rate exposure to radiation from the Chernobyl power station accident.

Rivkind N, Stepanenko V, Belukha I, Guenthoer J, Kopecky KJ, Kulikov S, Kurnosova I, Onstad L, Porter P, Shklovskiy-Kordi N, Troshin V, Voillequé P, Davis S.

Int J Epidemiol. 2019 Oct 19. pii: dyz214. doi: 10.1093/ije/dyz214. [Epub ahead of print]

PMID:
31628796
2.

Joint nonparametric correction estimator for excess relative risk regression in survival analysis with exposure measurement error.

Wang CY, Cullings H, Song X, Kopecky KJ.

J R Stat Soc Series B Stat Methodol. 2017 Nov;79(5):1583-1599. doi: 10.1111/rssb.12230. Epub 2017 Feb 27.

3.

Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, Meshinchi S, Stirewalt DL.

Biopreserv Biobank. 2018 Feb;16(1):42-52. doi: 10.1089/bio.2017.0079. Epub 2017 Nov 27. Erratum in: Biopreserv Biobank. 2018 Apr;16(2):168.

4.

Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.

Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C, Cohen AC, Hackett J, Shi J, Walker MG, Sun Z, Paietta E, Tallman MS, Cripe LD, Atwater S, Appelbaum FR, Radich JP.

PLoS One. 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485. eCollection 2015.

5.

Shared dosimetry error in epidemiological dose-response analyses.

Stram DO, Preston DL, Sokolnikov M, Napier B, Kopecky KJ, Boice J, Beck H, Till J, Bouville A.

PLoS One. 2015 Mar 23;10(3):e0119418. doi: 10.1371/journal.pone.0119418. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0126041.

6.

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

J Clin Oncol. 2015 Apr 1;33(10):1157-64. doi: 10.1200/JCO.2014.58.0571. Epub 2015 Feb 23. Erratum in: J Clin Oncol. 2015 May 20;33(15):1715.

7.

Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.

Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, Brandwein J, Larson RA, Stiff PJ, Walter RB, Tallman MS, Stenke L, Erba HP.

Biol Blood Marrow Transplant. 2015 Mar;21(3):559-64. doi: 10.1016/j.bbmt.2014.10.025. Epub 2014 Dec 20.

8.

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR.

Br J Haematol. 2014 May;165(4):497-503. doi: 10.1111/bjh.12775. Epub 2014 Feb 14.

9.

Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.

Edlefsen KL, Martínez-Maza O, Madeleine MM, Magpantay L, Mirick DK, Kopecky KJ, LaCroix AZ, De Roos AJ.

Int J Cancer. 2014 Aug 15;135(4):913-22. doi: 10.1002/ijc.28724. Epub 2014 Feb 3.

10.

Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.

Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR.

Leuk Res. 2014 Mar;38(3):329-33. doi: 10.1016/j.leukres.2013.12.001. Epub 2013 Dec 11.

11.

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ.

Br J Haematol. 2014 Jan;164(2):223-32. doi: 10.1111/bjh.12618. Epub 2013 Nov 4.

12.

The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.

Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

PLoS One. 2013 Aug 14;8(8):e70812. doi: 10.1371/journal.pone.0070812. eCollection 2013.

13.

Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort.

De Roos AJ, Martínez-Maza O, Jerome KR, Mirick DK, Kopecky KJ, Madeleine MM, Magpantay L, Edlefsen KL, Lacroix AZ.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1747-55. doi: 10.1158/1055-9965.EPI-13-0240. Epub 2013 Jul 24.

14.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK, Walter RB, Tallman MS, Stenke L, Appelbaum FR.

Blood. 2013 Jun 13;121(24):4854-60. doi: 10.1182/blood-2013-01-466706. Epub 2013 Apr 16.

15.

Relationship between anthropometric factors, radiation exposure, and colon cancer incidence in the Life Span Study cohort of atomic bomb survivors.

Semmens EO, Kopecky KJ, Grant E, Mathes RW, Nishi N, Sugiyama H, Moriwaki H, Sakata R, Soda M, Kasagi F, Yamada M, Fujiwara S, Akahoshi M, Davis S, Kodama K, Li CI.

Cancer Causes Control. 2013 Jan;24(1):27-37. doi: 10.1007/s10552-012-0086-8. Epub 2012 Oct 21.

PMID:
23085813
16.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ.

Blood. 2012 Nov 8;120(19):3898-905. doi: 10.1182/blood-2012-02-410688. Epub 2012 Aug 22.

17.

Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.

De Roos AJ, Mirick DK, Edlefsen KL, LaCroix AZ, Kopecky KJ, Madeleine MM, Magpantay L, Martínez-Maza O.

Cancer Res. 2012 Sep 15;72(18):4733-43. Epub 2012 Jul 30.

18.

Effects of radiation and lifestyle factors on risks of urothelial carcinoma in the Life Span Study of atomic bomb survivors.

Grant EJ, Ozasa K, Preston DL, Suyama A, Shimizu Y, Sakata R, Sugiyama H, Pham TM, Cologne J, Yamada M, De Roos AJ, Kopecky KJ, Porter MP, Seixas N, Davis S.

Radiat Res. 2012 Jul;178(1):86-98. Epub 2012 May 25.

PMID:
22631857
19.

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.

Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26.

20.

SWOG Cooperative Group biorepository resource: access for scientific research studies.

Hoban CJ, Franklin W, Kopecky KJ, Baker LH.

Clin Cancer Res. 2011 Aug 15;17(16):5239-46. doi: 10.1158/1078-0432.CCR-10-3138. Epub 2011 May 9.

21.

Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors.

Li CI, Nishi N, McDougall JA, Semmens EO, Sugiyama H, Soda M, Sakata R, Hayashi M, Kasagi F, Suyama A, Mabuchi K, Davis S, Kodama K, Kopecky KJ.

Cancer Res. 2010 Sep 15;70(18):7187-98. doi: 10.1158/0008-5472.CAN-10-0276.

22.

Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006.

De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, Bowles EJ, Yong M, Fryzek J, Davis S.

Am J Hematol. 2010 Oct;85(10):765-70. doi: 10.1002/ajh.21828.

23.

Timing of menarche and first birth in relation to risk of breast cancer in A-bomb survivors.

McDougall JA, Sakata R, Sugiyama H, Grant E, Davis S, Nishi N, Soda M, Shimizu Y, Tatsukawa Y, Kasagi F, Suyama A, Ross P, Kopecky KJ, Li CI.

Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1746-54. doi: 10.1158/1055-9965.EPI-10-0246. Epub 2010 Jun 22.

24.

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Leukemia. 2010 May;24(5):909-13. doi: 10.1038/leu.2010.56. Epub 2010 Apr 8.

25.

XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia.

Kuptsova-Clarkson N, Ambrosone CB, Weiss J, Baer MR, Sucheston LE, Zirpoli G, Kopecky KJ, Ford L, Blanco J, Wetzler M, Moysich KB.

Int J Mol Epidemiol Genet. 2010;1(4):278-94. Epub 2010 Aug 10.

26.

Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.

Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen IM, Willman CL, Kopecky KJ, Appelbaum FR.

Br J Haematol. 2010 Jan;148(1):48-58. doi: 10.1111/j.1365-2141.2009.07919.x. Epub 2009 Oct 11.

27.

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C.

JAMA. 2009 Jun 10;301(22):2349-61. doi: 10.1001/jama.2009.813. Review.

28.

Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation.

Schwartz JL, Kopecky KJ, Mathes RW, Leisenring WM, Friedman DL, Deeg HJ.

Radiat Res. 2009 Feb;171(2):155-63. doi: 10.1667/RR1469.1.

29.

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.

Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR.

Blood. 2009 Jan 22;113(4):866-74. doi: 10.1182/blood-2007-12-124818. Epub 2008 Oct 16.

30.

ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout.

Tuttle RM, Lukes Y, Onstad L, Lushnikov E, Abrosimov A, Troshin V, Tsyb A, Davis S, Kopecky KJ, Francis G.

Thyroid. 2008 Aug;18(8):839-46. doi: 10.1089/thy.2008.0072.

31.

Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism.

Hamilton TE, Davis S, Onstad L, Kopecky KJ.

J Clin Endocrinol Metab. 2008 Apr;93(4):1224-30. doi: 10.1210/jc.2006-2300. Epub 2008 Jan 29.

32.

Locating members of a cohort identified retrospectively from limited data in 50-year-old records: successful approaches employed by the Hanford Thyroid Disease Study.

Davis S, Onstad L, Kopecky KJ, Wiggins C, Hamilton TE.

Ann Epidemiol. 2008 Mar;18(3):187-95. doi: 10.1016/j.annepidem.2007.10.010. Epub 2008 Jan 16.

PMID:
18201901
33.

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.

Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.

Blood. 2008 Mar 1;111(5):2563-72. Epub 2007 Dec 21.

34.

Identification of genes with abnormal expression changes in acute myeloid leukemia.

Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP.

Genes Chromosomes Cancer. 2008 Jan;47(1):8-20.

PMID:
17910043
35.

Hypothesis testing, statistical power, and confidence limits in the presence of epistemic uncertainty.

Stram DO, Thomas DC, Kopecky KJ.

Health Phys. 2007 Oct;93(4):326-7; author reply 327-8. No abstract available.

PMID:
17846531
36.

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.

Kuptsova N, Kopecky KJ, Godwin J, Anderson J, Hoque A, Willman CL, Slovak ML, Ambrosone CB.

Blood. 2007 May 1;109(9):3936-44. Epub 2006 Dec 29.

PMID:
17197435
37.

Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials.

Weiss JR, Kopecky KJ, Godwin J, Anderson J, Willman CL, Moysich KB, Slovak ML, Hoque A, Ambrosone CB.

Leukemia. 2006 Dec;20(12):2169-71. Epub 2006 Sep 28. No abstract available.

PMID:
17008887
38.

Microarray comparative genomic hybridization reveals genome-wide patterns of DNA gains and losses in post-Chernobyl thyroid cancer.

Kimmel RR, Zhao LP, Nguyen D, Lee S, Aronszajn M, Cheng C, Troshin VP, Abrosimov A, Delrow J, Tuttle RM, Tsyb AF, Kopecky KJ, Davis S, Neiman PE.

Radiat Res. 2006 Sep;166(3):519-31.

PMID:
16953671
39.

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH.

Br J Haematol. 2006 Oct;135(2):165-73. Epub 2006 Aug 25.

PMID:
16939487
40.

Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study.

Kopecky KJ, Stepanenko V, Rivkind N, Voillequé P, Onstad L, Shakhtarin V, Parshkov E, Kulikov S, Lushnikov E, Abrosimov A, Troshin V, Romanova G, Doroschenko V, Proshin A, Tsyb A, Davis S.

Radiat Res. 2006 Aug;166(2):367-74.

PMID:
16881738
41.

Cancer consequences of the Chernobyl accident: 20 years on.

Cardis E, Howe G, Ron E, Bebeshko V, Bogdanova T, Bouville A, Carr Z, Chumak V, Davis S, Demidchik Y, Drozdovitch V, Gentner N, Gudzenko N, Hatch M, Ivanov V, Jacob P, Kapitonova E, Kenigsberg Y, Kesminiene A, Kopecky KJ, Kryuchkov V, Loos A, Pinchera A, Reiners C, Repacholi M, Shibata Y, Shore RE, Thomas G, Tirmarche M, Yamashita S, Zvonova I.

J Radiol Prot. 2006 Jun;26(2):127-40. Epub 2006 Apr 24. Review.

PMID:
16738412
42.

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL.

Blood. 2006 Jul 15;108(2):685-96. Epub 2006 Apr 4.

43.

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP.

Blood. 2006 May 1;107(9):3724-6. Epub 2005 Dec 20.

44.

Childhood leukaemia in Belarus, Russia, and Ukraine following the Chernobyl power station accident: results from an international collaborative population-based case-control study.

International Consortium for Research on the Health Effects of Radiation Writing Committee and Study Team, Davis S, Day RW, Kopecky KJ, Mahoney MC, McCarthy PL, Michalek AM, Moysich KB, Onstad LE, Stepanenko VF, Voillequé PG, Chegerova T, Falkner K, Kulikov S, Maslova E, Ostapenko V, Rivkind N, Shevchuk V, Tsyb AF.

Int J Epidemiol. 2006 Apr;35(2):386-96. Epub 2005 Nov 3.

PMID:
16269548
45.

Hyperparathyroidism in persons exposed to iodine-131 from the Hanford Nuclear Site.

Hamilton TE, Davis S, Onstad L, Kopecky KJ.

J Clin Endocrinol Metab. 2005 Dec;90(12):6545-8. Epub 2005 Oct 4.

PMID:
16204367
46.

Thyroid ultrasound abnormalities in persons exposed during childhood to 131I from the Hanford nuclear site.

Kopecky KJ, Onstad L, Hamilton TE, Davis S.

Thyroid. 2005 Jun;15(6):604-13.

PMID:
16029129
47.

Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site.

Davis S, Kopecky KJ, Hamilton TE, Onstad L; Hanford Thyroid Disease Study Team.

JAMA. 2004 Dec 1;292(21):2600-13.

PMID:
15572718
48.

Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine.

McCarthy PL Jr, Paltiel O, Maslova E, Kulikov S, Hahn T, Kopecky KJ, Drozdova V, Shmatina N, Tichonova L, Van Hoff J, Gavrilova I, Weinstein H.

Leuk Res. 2004 Dec;28(12):1273-80.

PMID:
15475068
49.

Risk of thyroid cancer in the Bryansk Oblast of the Russian Federation after the Chernobyl Power Station accident.

Davis S, Stepanenko V, Rivkind N, Kopecky KJ, Voillequé P, Shakhtarin V, Parshkov E, Kulikov S, Lushnikov E, Abrosimov A, Troshin V, Romanova G, Doroschenko V, Proshin A, Tsyb A.

Radiat Res. 2004 Sep;162(3):241-8.

PMID:
15332999
50.

Supplemental Content

Loading ...
Support Center